7-氯-5-甲基吡唑并[1,5-A]嘧啶-3-羧酸乙酯 | 58347-48-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 中文名称: 7-氯-5-甲基吡唑并[1,5-A]嘧啶-3-羧酸乙酯
• 英文名称: ethyl 7-chloro-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxylate
• CAS: 58347-48-1
• 化学式: C₁₀H₁₀ClN₃O₂
• 分子量: 239.661
• InChiKey: SSFMULHSDYYZIN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  56.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  7-氯-5-甲基吡唑并[1,5-A]嘧啶-3-羧酸乙酯 以98%的产率得到
  参考文献：
  名称：

  NOVINSON T.; BHOOSHAN B.; OKABE T.; REVANKAR G. R.; ROBINS R. K.; SENGA K+, J. MED. CHEM. , 1976, 19, NO 4, 512-516

  摘要：

  DOI：
• 作为产物：
  描述：

  Ethyl 7-hydroxy-5-methylpyrazolo[1,5-a]pyrimidine-3-carboxylate 在 N,N-二甲基苯胺 、 三氯氧磷 作用下， 反应 1.0h， 生成 7-氯-5-甲基吡唑并[1,5-A]嘧啶-3-羧酸乙酯
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZOLO/IMIDAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS
  [FR] COMPOSÉS BICYCLIQUES PYRAZOLO/IMIDAZOLO SUBSTITUÉS EN TANT QU'INHIBITEURS DE PDE2

  摘要：

  本发明涉及式I的嘧啶羧酰胺化合物，其可用作治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病的治疗剂。本发明还涉及利用这些化合物治疗神经系统和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能不足或基底节功能障碍相关的疾病。

  公开号：

  WO2016209749A1

文献信息

• [EN] SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] PYRAZOLO(1,5-A)PYRIMIDINES SUBSTITUÉES ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2016073895A1

  公开（公告）日：2016-05-12

  The invention provides substituted pyrazolo[l,5-a]pyrimidine and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrazolo[l,5-a]pyrimidine compounds described herein include 5,7- dimethyl-N-phenylpyrazolo[l,5-a]pyrimidine-3-carboxamide compounds and variants thereof.

  这项发明提供了替代的吡唑并[1,5-a]嘧啶和相关的有机化合物，包含这些化合物的组合物，医疗工具包，以及使用这些化合物和组合物治疗医疗疾病的方法，例如高雪氏病、帕金森病、Lewy小体病、痴呆症或多系统萎缩症。本文描述的示例替代的吡唑并[1,5-a]嘧啶化合物包括5,7-二甲基-N-苯基吡唑并[1,5-a]嘧啶-3-羧酰胺化合物及其变体。
• [EN] SUBSTITUTED PYRAZOLO/IMIDAZOLO BICYCLIC COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS BICYCLIQUES PYRAZOLO/IMIDAZOLO SUBSTITUÉS EN TANT QU'INHIBITEURS DE PDE2
  申请人：MERCK SHARP & DOHME

  公开号：WO2016209749A1

  公开（公告）日：2016-12-29

  The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及式I的嘧啶羧酰胺化合物，其可用作治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病的治疗剂。本发明还涉及利用这些化合物治疗神经系统和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能不足或基底节功能障碍相关的疾病。
• Cephalosporin .beta.-lactam compound and medicinal composition
  申请人：Sankei Pharmaceutical Company Ltd.

  公开号：US04966900A1

  公开（公告）日：1990-10-30

  There are disclosed a .beta.-lactam compound represented by the formula (I): ##STR1## wherein R.sub.1 and R.sub.2 are independently a hydrogen atom or a lower alkyl group; M is a hydrogen atom, a protective group or an eliminatable group which is easily hydrolyzable in a human body; R' and R" are independently a hydrogen atom or a protective group; A is a mercapto group substituted by a substituted or unsubstituted polycyclic nitrogen-containing heterocyclic ring or a group represented by the following formula (a): --OOCNR.sub.3 R.sub.4 (a) where R.sub.3 and R.sub.4 are independently a hydrogen atom or a lower alkyl group, provided that R.sub.1 and R.sub.2 are both hydrogen atoms, both R.sub.3 and R.sub.4 being hydrogen atoms are excluded, or its pharmaceutically acceptable salt, and a method for preparing the same , medicinal composition for microbism therapy containing the same and intermediates for synthesis of the same.

  公开了一种β-内酰胺化合物，其由式（I）表示：##STR1##其中R1和R2分别是氢原子或较低的烷基基团; M是氢原子、保护基或易于在人体内水解的可消除基团; R'和R"分别是氢原子或保护基; A是被取代或未取代的多环氮杂环环或由以下式(a)表示的基团取代的巯基基团：--OOCNR3R4(a)，其中R3和R4分别是氢原子或较低的烷基基团，前提是R1和R2都是氢原子，当R3和R4均为氢原子时被排除，或其药学上可接受的盐，并且公开了其制备方法，含有该化合物的抗微生物治疗药物组合物以及合成该化合物的中间体。
• Beta-Lactam compound, method for preparing the same, medicinal composition for bacterially infectious disease therapy containing the same and intermediates for synthesis of the same
  申请人：SANKEI PHARMACEUTICAL COMPANY LIMITED

  公开号：EP0254495A2

  公开（公告）日：1988-01-27

  There are disclosed a β-lactam compound represented by the formula (I): wherein R₁ and R₂ are independently a hydrogen atom or a lower alkyl group; M is a hydrogen atom, a protective group or an eliminatable group which is easily hydrolyzable in a human body; Rʹ and Rʺ are independently a hydrogen atom or a protective group; A is a mercapto group substituted by a sub­stituted or unsubstituted polycyclic nitrogen-con­taining heterocyclic ring or a group represented by the following formula (a):     -OOCNR₃R₄      (a) where R₃ and R₄ are independently a hydrogen atom or a lower alkyl group, provided that R₁ and R₂ are both hydrogen atoms, both R₃ and R₄ being hydrogen atoms are excluded, or its pharmaceutically acceptable salt, and a method for preparing the same, medicinal composition for microbism therapy containing the same and intermediates for synthesis of the same.

  本发明公开了一种β-内酰胺化合物，由式(I)表示： 其中 R₁ 和 R₂ 独立地为氢原子或低级烷基；M 为氢原子、保护基团或在人体内易水解的可消除基团；Rʹ 和 Rʺ 独立地为氢原子或保护基团；A 为被取代或未取代的多环含氮杂环取代的巯基或下式(a)所代表的基团： -OOCNR₃R₄ (a) 其中 R₃ 和 R₄ 独立地为氢原子或低级烷基、 但 R₁ 和 R₂ 均为氢原子，R₃ 和 R₄ 均为氢原子者除外、 或其药学上可接受的盐，以及制备上述物质的方法、含有上述物质的微生物治疗药物组合物和合成上述物质的中间体。
• Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders
  申请人：Lysosomal Therapeutics Inc.

  公开号：US10570135B2

  公开（公告）日：2020-02-25

  The invention provides substituted pyrazolo[1,5-a]pyrimidine and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrazolo[1,5-a]pyrimidine compounds described herein include 5,7-dimethyl-N-phenylpyrazolo[1,5-a]pyrimidine-3-carboxamide compounds and variants thereof.

  本发明提供了取代的吡唑并[1,5-a]嘧啶及相关有机化合物、含有此类化合物的组合物、医用试剂盒以及使用此类化合物和组合物治疗患者的内科疾病（如戈谢病、帕金森病、路易体病、痴呆症或多系统萎缩）的方法。本文所述的示例性取代吡唑并[1,5-a]嘧啶化合物包括5,7-二甲基-N-苯基吡唑并[1,5-a]嘧啶-3-甲酰胺化合物及其变体。